Atacicept as an investigated therapy for rheumatoid arthritis

Expert Opinion on Investigational Drugs

Volumn 23, Issue 9, 2014, Pages 1285-1294

  Richez, Christophe ^a,b   Truchetet, Marie Elise ^a,b   Schaeverbeke, Thierry ^a   Bannwarth, Bernard ^a  

^a HÔPITAL PELLEGRIN   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Atacicept; B cell; B lymphocyte stimulator and a proliferation inducing ligand; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; CYTOKINE; IMMUNOGLOBULIN; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; HYBRID PROTEIN; TACI RECEPTOR-IGG FC FRAGMENT FUSION PROTEIN;

AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOGLOBULIN PRODUCTION; INFECTION; INFECTION SENSITIVITY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; ANIMAL; ARTHRITIS, RHEUMATOID; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL SURVIVAL; HUMANS; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84906050258     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.943835     Document Type: Review

References (52)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365(23):2205-19
2. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011;63(3):633-9
3. Bannwarth B, Kostine M, Poursac N. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol 2013;9(6):753-61
4. Shahouri SH, Michaud K, Mikuls TR, et al. Remission of rheumatoid arthritis in clinical practice: Application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum 2011;63(11):3204-15
5. Bugatti S, Codullo V, Caporali R, et al. B cells in rheumatoid arthritis. Autoimmun Rev 2007;7(2):137-42
6. Burmester GR, Feist E, Dorner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014;10(2):77-88
7. Moore PA, Belvedere O, Orr A, et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285(5425):260-3
8. Dillon SR, Gross JA, Ansell SM, et al. An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006;5(3):235-46
9. Bossen C, Cachero TG, Tardivel A, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008;111(3):1004-12
10. Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3(9):822-9
11. Thompson JS, Schneider P, Kalled SL, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 2000;192(1):129-35
12. Batten M, Groom J, Cachero TG, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192(10):1453-66
13. Hsu BL, Harless SM, Lindsley RC, et al. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002;168(12):5993-6
14. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogrens syndrome. J Clin Invest 2002;109(1):59-68
15. Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44(6):1313-19
16. Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169(8):4314-21
17. Stohl W, Hilbert DM. The discovery and development of belimumab: The anti-BLyS-lupus connection. Nat Biotechnol 2012;30(1):69-77
18. Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single-And repeated-dose study. Arthritis Rheum 2008;58(1):61-72
19. DallEra M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, double-blind, placebocontrolled, dose-escalating trial. Arthritis Rheum 2007;56(12):4142-50
20. Munafo A, Priestley A, Nestorov I, et al. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 2007;63(7):647-56
21. Nestorov I, Munafo A, Papasouliotis O, et al. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 2008;48(4):406-17
22. Bracewell C, Isaacs JD, Emery P, et al. Atacicept, a novel B cell-Targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2009;9(7):909-19
23. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001;15(2):289-302
24. Genovese MC, Kinnman N, De La Bourdonnaye G, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011;63(7):1793-803
25. Van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011;63(7):1782-92
26. Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. Arthritis Res Ther 2012;14(1):R33
27. Wofsy D, Isenberg D, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in subjects with moderate to severe systemic lupus erythematosus [abstract #2122]. Arthritis Rheum 2013;65(9 Suppl):S675
28. Ansell SM, Witzig TE, Inwards DJ, et al. Phase I clinical study of atacicept in patients with relapsed and refractory Bcell non-Hodgkins lymphoma. Clin cancer Res 2008;14(4):1105-10
29. Rossi JF, Moreaux J, Hose D, et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstroms macroglobulinemia: A phase I study. Br J cancer 2009;101(7):1051-8
30. Kofler DM, Gawlik BB, Elter T, et al. Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia. Leukemia 2012;26(4):841-4
31. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373(9664):659-72
32. Anolik JH, Looney RJ, Lund FE, et al. Insights into the heterogeneity of human B cells: Diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009;45(2-3):144-58
33. Bluml S, McKeever K, Ettinger R, et al. B-cell targeted therapeutics in clinical development. Arthritis Res Ther 2013;15(Suppl 1):S4
34. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54(5):1390-400
35. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-Tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54(9):2793-806
36. Rigby W, Tony HP, Oelke K, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012;64(2):350-9
37. Stohl W, Gomez-Reino J, Olech E, et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: The phase III FILM trial. Ann Rheum Dis 2012;71(8):1289-96
38. Tak PP, Mease PJ, Genovese MC, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, doubleblind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012;64(2):360-70
39. Stohl W, Merrill JT, McKay JD, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: A phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol 2013;40(5):579-89
40. Genovese MC, Fleischmann RM, Greenwald M, et al. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis 2013;72(9):1461-8
41. Genovese MC, Bojin S, Biagini IM, et al. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: A phase II, randomized, placebo-controlled trial. Arthritis Rheum 2013;65(4):880-9
42. Dass S, Vital EM, Emery P. Rituximab: Novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2006;7(18):2559-70
43. Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008;180(6):3655-9
44. Fernandez L, Salinas GF, Rocha C, et al. The TNF family member APRIL dampens collagen-induced arthritis. Ann Rheum Dis 2013;72(8):1367-74
45. Taylor PC, Quattrocchi E, Mallett S, et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: A randomised, doubleblind, placebo-controlled clinical trial. Ann Rheum Dis 2011;70(12):2119-25
46. Isaacs JD, Manna VK, Rapson N, et al. CAMPATH-1H in rheumatoid arthritis-An intravenous dose-ranging study. Br J Rheumatol 1996;35(3):231-40
47. Lorenzi AR, Clarke AM, Wooldridge T, et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes. Arthritis Rheum 2008;58(2):370-5
48. Roll P, Muhammad K, Schumann M, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum 2011;63(5):1255-64
49. Muhammad K, Roll P, Seibold T, et al. Impact of IL-6 receptor inhibition on human memory B cells in vivo: Impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis 2011;70(8):1507-10
50. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-Tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67(11):1516-23
51. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional diseasemodifying antirheumatic drug therapy study. Arthritis Rheum 2008;58(10):2968-80
52. Bannwarth B, Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 2011;10(1):123-31.